Russia Successfully Trials Breakthrough mRNA Cancer Vaccine. In a major leap forward in the fight against cancer, Russia has announced the successful trial of a groundbreaking mRNA-based cancer vaccine named Enteromix. Developed by the Federal Medical and Biological Agency (FMBA), the vaccine has shown promising preclinical results and is now ready for patient use, according to official reports.
Speaking at the Eastern Economic Forum, FMBA head Veronika Skvortsova confirmed that three years of intensive research and testing have proven the vaccine to be completely safe, even after multiple doses. Most notably, in preclinical trials, Enteromix reduced tumor size by 60% to 80%, depending on the cancer type, or significantly slowed tumor growth. The survival rate of patients also improved remarkably following vaccination.
First Target: Colon Cancer — With Plans to Tackle Brain and Skin Cancers Next
Initially, the vaccine will be used for the treatment of colon cancer, but scientists have expressed optimism about its broader application. There are already plans to adapt the vaccine for combating glioblastoma (a fast-growing type of brain cancer) and various forms of melanoma (a severe cancer of the skin and eyes).
Powered by mRNA Technology — The Same Used in COVID-19 Vaccines
Enteromix utilizes messenger RNA (mRNA) technology, which became widely known during the global COVID-19 pandemic. This innovative approach teaches the body’s weakened cells to produce specific proteins. These proteins then trigger the immune system to identify and destroy cancer cells on its own.
Approval Process Underway — A Global First?
The vaccine is currently undergoing the registration and approval process. If approved, Enteromix could become the world’s first effective and safe cancer vaccine, revolutionizing how we approach cancer treatment globally.
Source: TASS News Agency